Aventis Ketek complete response
This article was originally published in Pharmaceutical Approvals Monthly
New user fee goal for Aventis' ketolide antibiotic Ketek (telithromycin) is presumably in January, following the firm's July 24 response to a June 1, 2001 "approvable" letter. Aventis submitted data from a 24,000-patient trial comparing Ketek to GlaxoSmithKline's Augmentin (amoxicillin/clavulanate) for the treatment of respiratory tract infection to address FDA's request for additional liver and cardiovascular safety data (Pharmaceutical Approvals Monthly, August 2001, In Brief). FDA's Anti-Infective Drugs Advisory Committee voted against efficacy for community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis in April 2001, citing QT prolongation and liver toxicity concerns, and requested data from a larger patient populatio
You may also be interested in...
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from Bill Gates, it has a chance to prove the doubters wrong
Exclusive: How are import/export restrictions both within and outside the European Union affecting the food supplements industry supply chain? HBW Insight speaks to Food Supplements Europe and the International Alliance of Dietary/Food Supplements Associations to find out.
Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.